Gem Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy. Gem is working on transforming traditional broad-spectrum cytotoxic drugs into modern - and biochemically targeted - anti-cancer agents that hold the potential for higher dosing and correspondingly improved therapeutic utility. Gem's anthracycline-modification platform can also be used to generate safe and effective derivatives that could serve as long-term therapies for psoriasis, rheumatoid arthritis, and other T-cell mediated disorders. In November 2017, a primary asset of the firm (GPX-150) was sold to Monopar Therapeutics an emerging biopharmaceutical company focused on developing innovative drug candidates to improve clinical outcomes in cancer patients
